Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipne ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension
- 15 April 1995
- journal article
- clinical trial
- Published by Elsevier in The American Journal of Cardiology
- Vol. 75 (12) , 793-795
- https://doi.org/10.1016/s0002-9149(99)80413-5
Abstract
No abstract availableKeywords
This publication has 3 references indexed in Scilit:
- Comparison of Angiotensin-Converting Enzyme Inhibition with Angiotensin II Receptor Antagonism in the Human ForearmJournal of Cardiovascular Pharmacology, 1993
- Pharmacology of Nonpeptide Angiotensin II Receptor AntagonistsAnnual Review of Pharmacology and Toxicology, 1992
- Oral administration of DuP 753, a specific angiotensin II receptor antagonist, to normal male volunteers. Inhibition of pressor response to exogenous angiotensin I and II.Circulation, 1991